# A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)

> **NCT05192356** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 63 (actual)

## Conditions studied

- Hypertension and Dyslipidemia

## Interventions

- **DRUG:** CKD-348(3)
- **DRUG:** CKD-828, D097, D337

## Key facts

- **NCT ID:** NCT05192356
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-23
- **Primary completion:** 2022-05-08
- **Final completion:** 2022-06-08
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192356, "A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05192356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*